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ABSTRACT
Introduction: Prostate cancer is reported to be the leading cancer in men in Sub-Saharan 
Africa (SSA) and the number of prostate cancer deaths is expected to double in the next 20 
years. Despite the importance of this public health issue in SSA, there remains relatively 
limited information about practices related to prostate cancer treatment in this population. 
Objective: We conducted a survey of 28 urology practices in SSA to evaluate the scope of 
available screening, detection and treatment. 
Materials and Methods: Screening was more commonly reported as a part of general 
medical care in South Africa (SA) compared with East or West (EW) Africa.  However, 
use of digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) were used 
at similar rates for screening in all locations. Screening is primarily focused in men over 
age 50 and those with symptoms. Routine screening was the primary reason for screening 
use in SA, while symptoms were the primary reason for screening use in EW. Financial 
and cultural barriers to screening were more commonly reported in EW than SA. Similar 
detection approaches were used in all regions, with free PSA and PSA velocity being more 
commonly used in SA than EW. Six core biopsies were more commonly used in EW and 12 
core biopsies were more common in SA. Trans urethral ultrasounds and bone scans were 
more commonly used in SA than EW. Treatment options were similar in all regions, with 
brachytherapy less likely to be used in EW than SA. 
Results: The descriptive data suggest that differences in patterns of screening, detection 
and treatment exist across Africa. Differences by geography may also reflect differences in 
SES and racial composition of the populations in each region.
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INTRODUCTION                                    
Relatively little is known about the 
epidemiology of Prostate cancer (PCa) 
in men in Sub-Saharan Africa (SSA), 
however it is clear that men of SSA descent 
around the world suffer disproportiona-
tely from PCa1. The International Agency 
for Research on Cancer (IARC) estimates 
that PCa is the leading cancer in terms 
of incidence and mortality in Africa and 
that PCa is a growing problem in Africa: 
Approximately 29.707 African men will 
die of PCa in 2010 and approximately 
57.048 African men will die of PCa in 
20302. This represents a 92% increase in 
the number of PCa deaths in Africa in the 
next two decades.  
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Unfortunately, data are not available to 
address whether changes in PCa screening 
and detection practices have made an 
impact on PCa incidence or mortality in 
SSA. Based on time trend data from 
population-based tumor registries in 
Kampala (2002-2006)3 and Kyadondo 
(1991-1994)4 in Uganda and Harare in 
Zimbabwe (1990-1997)5, there appears to be 
a small and steady increase in PCa incidence 
in the past two decades, with no spike in 
incidence during the period where PSA 
screening became prevalent such as has been 
observed in the US, However, there has been 
concern that PCa incidence and mortality 
rates in SSA may be underestimated due to 
lack of screening, limited population-based 
tumor registry data and under-diagnosis6.  
While PCa is likely to represent a major 
contributor to the overall burden of cancer 
in Africa, practices related to PCa screening, 
detection, diagnosis and treatment are poorly 
described. To provide baseline information 
about PCa clinical practices in SSA, we 
have undertaken a non-random survey of 
urologists practicing in SSA and describe 
those practices here.
MATERIALS AND METHODS                         
We identified urologists through internatio-
nal organizations including the Pan-African 
Urological Surgeons’ Association (PAUSA), 
the African Organization for Research and 
Training in Cancer (AORTIC) and the South 
African Urological Association (SAUA). 
We solicited a single respondent from 
each institution to respond to a web-based 
questionnaire about PCa practices rela-
ted to screening, detection, diagnosis and 
treatment. The questionnaire is presented 
as supplementary information. Tabulations 
were made of all responses. Due to the small 
numbers of centers represented, no statistical 
analyses were undertaken in this descriptive 
report.
RESULTS                                                     
We received responses from 28 institutions 
in three African regions: East Africa 
(Sudan, Tanzania, Uganda, N= 5), the 
Republic of South Africa (N= 18) and West 
Africa (Ghana, Nigeria, Senegal, N=5). These 
institutions represented general hospitals 
(N= 8), private practice urologists (N= 13), 
specialized cancer centers (N= 4), two other 
practice settings (not specified) and one 
university hospital.
Screening and Detection
Screening is not a routine part of medical 
care in East and West Africa, but is relatively 
common in South Africa (Table 1). In all 
cases, more men are screened if they are 
over age 50 or have urinary symptoms than 
men who are under age 50. Men who are 
identified as having a family history of PCa 
are also commonly screened in South and 
West Africa, but less so in East Africa. Digital 
Rectal Examination (DRE) is commonly 
used as a means of PCa detection.  Similar 
patterns of DRE usage were reported in 
each of the regions. In general, screening 
is reported to be less widely used in East 
Africa than West or South Africa.
When asked about the patients’ perceived 
reasons for not undergoing screening at their 
centers, the respondents identified lack of un-
derstanding/knowledge and financial constraints 
as the most common reasons that screening 
was not undertaken. Access was also an im-
portant factor in East and West Africa, but less 
so in South Africa. Fear was cited by more than 
half of respondents in South and West Africa, 
but not in East Africa. Less common rea-
sons for lack of screening were religious and 
cultural reasons, although these reasons were 
more common in West Africa than in East or 
South Africa. The majority of cases of PCa in 
East and West Africa are detected via symp-
toms, while the majority of cases in South 
Africa are detected by screening (Table 1).
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Topic Question East Africa*(N=5)
West Africa** 
(N= 5)





Is prostate cancer screening a 
routine part of general medical 
care?
0 0 0 61
Is PSA screening usually 
offered or performed during 
routine physical examinations?
60 80 70 89
If yes, what groups are 
typically offered screening?
Men under age 50 0 20 10 6
Men over age 50 40 60 50 72
Men with urinary symptoms 40 60 50 56
Men at high risk (e.g. family 
history positive) 20 80 50 67
Is DRE screening usually 
offered or performed during 
routine physical examinations?
60 100 80 94
If yes, what groups are 
typically offered screening?
Men under age 50 0 40 20 22
Men over age 50 40 100 70 67
Men with urinary symptoms 40 100 70 78
Men at high risk (e.g. family 
history positive) 40 100 70 72
What are the patient's perceived 
obstacles to prostate cancer 
screening?
Lack of understanding/
knowledge 60 80 70 72
Financial 60 100 80 50
Religious 0 20 10 0
Cultural 0 40 20 11
Access 80 80 80 28
Fear 0 60 30 50
Detection
What is the most common 
reason for prostate cancer 
detection?
Routine screening 20 20 20 72
Urinary symptoms 60 80 70 28
*Uganda, Sudan, Tanzania; **Senegal, Ghana, Nigeria
Table 1: Screening and Detection: Percent of Centers Responding in the Affirmative
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Topic Question East Africa* (N= 5)
West Africa** 
(N= 5)





What information is commonly 
used for prostate cancer detection 
and diagnosis?
Biopsy 100 100 100 100
Total PSA 80 100 90 83
Free PSA 100 20 60 44
PSA velocity 20 40 30 17
DRE 60 100 80 83
Transrectal ultrasound (TRUS) 20 20 20 28
What approaches are commonly 
used in diagnosis and staging?
PSA 60 100 80 100
DRE 80 100 90 100
6-core biopsy 80 80 80 17
12-core Biopsy 0 40 20 72
Other biopsy 20 20 20 17
Transrectal ultrasound (TRUS) 40 40 40 89
Bone scan 40 80 60 89
Chest X-Ray 60 60 60 17
CT scan 40 80 60 6
MRI scan 0 40 20 11
Lymph node biopsy 0 0 0 11
Treatment
Which treatment options are 
available to prostate cancer 
patients atyour center?
Prostatectomy 80 80 80 94
Robotic prostatectomy 0 0 0 0
Radiation after prostatectomy 0 60 30 16
External beam radiation 40 100 70 83
Brachytherapy 0 40 20 72
High intensity focused 
ultrasound (HIFU) 0 0 0 11
Intensity modulated radiation 
therapy (IMRT) 0 0 0 6
Robotic radiosurgery                   
(e.g. Cyberknife) 0 0 0 0
Table 2: Diagnosis and Treatment: Percent of Centers Responding in the Affirmative
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Diagnosis and Treatment
For diagnosis of PCa, biopsy is used by 
all respondents and total PSA is used by 
most (Table 2). Free PSA is reported to be 
used by all East African respondents but far 
fewer in South and West Africa. DRE was 
also commonly used, but again apparently 
less common in East Africa than West Africa. 
PSA velocity and TRUS were less commonly 
reported in all regions. In terms of diagnostic 
and staging approaches, PSA and DRE were 
again used by all South and West African 
respondents, but fewer East African centers. 
6-core biopsies were the most commonly 
used formats in East and West Africa, while 
12-core biopsies were more commonly 
reported in South Africa. TRUS was more 
widely reported in South Africa than in 
other regions, while chest X-rays were more 
commonly reported in East and West Africa 
than South Africa. In contrast, CT scans 
were reported to be more widely used in East 
and West Africa than South Africa. Other 
approaches including MRI and lymph node 
biopsies were less commonly reported. Bone 
scans were common in South and West Africa 
and less so in East Africa. In all regions, 
the most commonly used means of PCa 
treatment were prostatectomy and androgen 
deprivation therapy (including orchiectomy). 
Other common treatments included external 
beam radiation therapy, chemotherapy and 
expectant management with PSA screening 
(particularly in South and West Africa). 
Many more recent or equipment-intensive 
therapy modalities were not widely reported 
in the respondents’ institutions (Table 2).
DISCUSSION                                              
We report on practices related to PCa 
screening, detection, diagnosis and treatment 
in sub-Saharan Africa. These data suggest that 
there are differences in the usage of some of 
these modalities in Africa compared to the US 
and Europe and regional differences within 
Africa also exist. However, we also note that 
when data from East and West Africa were 
combined (Tables 1 and 2), it appears that 
some differences between East, South and 
West Africa disappear. 
In the developed world, there remains 
considerable debate about the optimal 
use of screening, detection, diagnosis and 
treatment modalities to minimize morbidity 
and mortality from PCa. Overall survival 
in men who are diagnosed with PCa at an 
early stage is significantly better than in men 
diagnosed later7, making early detection 
important for some men. While many PCa’s 
that are detected by screening and are treated 
surgically have clinical significance to the 
Cryotherapy 0 0 0 0
Androgen deprivation therapy 
(including orchiectomy) 60 100 80 100
Other hormone therapy 20 80 50 56
Chemotherapy 40 80 60 67
Expectant management with 
periodic PSA 40 60 50 89
Expectant management with 
periodic PSA and prostatic acid 
phosphatase
0 40 20 27
*Uganda, Sudan, Tanzania; **Senegal, Ghana, Nigeria
90
PROSTATE CANCER SCREENING, DETECTION AND TREATMENT
patient8, 9, even tumors with a potentially poor 
prognosis may not lead to significant morbidity 
or mortality, particularly in older men.  More 
recently, two large randomized studies did not 
show a mortality benefit from the use of PSA 
screening10 or showed a mortality benefit but 
also noted that an unacceptable number of 
men needed to be treated in order to show 
a mortality benefit11. Controversy therefore 
exists about what kind of treatment (if any) 
should be pursued in these cases12. Unnecessary 
treatments may result in morbidity that could 
be avoided if tumors destined to an indolent 
course could be identified13. 
Debate continues on these points in the 
developed world and the optimal use of PCa 
screening, detection, diagnosis and treatment 
regimens in Africa have not been established. 
As shown by the data presented here, access 
to a complete range of options remains limited 
in some parts of Africa and many men are not 
diagnosed at an early stage. Earlier reports of 
PCa in Africa suggest that PCa is diagnosed at 
higher tumor stage and grade than in Europe 
or the US14.  
There are many limitations to this 
descriptive report. This survey represents 
a non-random sample of practitioners in 
Africa based on access to urologists who are 
active in professional organizations and were 
accessible by email. Based on their practice 
distributions, these clinicians may reflect a 
more referral center sample than all urologists. 
The sample size was also relatively small, 
and we cannot make inferences about how 
representative this sample is of all urologists in 
Africa.Nonetheless, the number of urologists 
practicing in Africa is relatively small. It has 
been estimated that there are approximately 
120 urologists in West Africa, 64 in East 
Africa and approximately 220 members of 
the South African Urological Association. The 
Pan-African Urological Surgeons’ Association 
(PAUSA) has approximately 80 members.  
The 2009 American Urological Association 
(AUA) recommendations on PSA screening15 
advise that men should be offered screening 
starting at age 40 who have a life expectancy 
of at least 10 years. Screening should include 
both a PSA test and a Digital Rectal Exam 
(DRE), although the AUA recommendations 
also state that the decision to undergo testing 
is a personal decision that should be made in 
terms of the risks and benefits, including the 
risk of over-detection of cancers which may 
not need treatment. Our data suggest that 
screening is generally only applied in men 
over age 50 in SSA. In addition, the AUA 
does recommend a single PSA threshold at 
which a biopsy is indicated. PSA levels in 
men who are newly diagnosed with PCa are 
typically higher in African men than men 
in the US or Europe14 and no standard for a 
PSA level that may trigger prostate biopsy 
has been established specifically for African 
men. Screening in East and West Africa 
tends to be total PSA, with free PSA and PSA 
velocity not being used as widely.
Other aspects of prostate cancer practice 
recommended by the AUA include no need 
for bone scan to stage asymptomatic men 
with clinically localized prostate cancer if 
their PSA level is equal to or less than 20.0 
ng/ml. CT or MRI may be used in staging of 
high-risk clinically localized prostate cancer 
when the PSA is greater than 20.0 ng/mL or 
when locally advanced or when the Gleason 
score is greater than or equal to 8. In Africa, 
we observed that CT scans were commonly 
used in EW Africa, while MRI was more 
common in SA.
We did not solicit or receive responses 
from clinicians in other disciplines who 
may diagnose or treat PCa, including general 
internists, radiation oncologists, medical 
oncologists and others. Therefore, the spectrum 
of practice remains somewhat limited. 
In addition, our data do not distinguish practice 
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preferences from availability of screening, 
diagnosis, detection, or treatment modalities. 
Some centers may not have access to specific 
modalities, while other centers may choose 
not to use these modalities and/or have not 
developed them at their institution because 
they do not value them as part of clinical care.
While anecdotal, these results provide 
information about practices of screening, 
detection and treatment of PCa in SSA, 
where relatively limited information about 
these practices is available. Using these and 
other related data, a better understanding 
of practice patterns can be identified to 
develop practice recommendations that are 
appropriate for SSA populations and will 
provide optimal benefit for men in SSA to 
minimize morbidity and mortality from PCa.
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